(Q34499662)

English

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours (English)

1 reference

Europe PubMed Central

2 August 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I Brana

1

1 reference

Europe PubMed Central

2 August 2017

R Berger

2

1 reference

Europe PubMed Central

2 August 2017

T Golan

3

1 reference

Europe PubMed Central

2 August 2017

P Haluska

4

1 reference

Europe PubMed Central

2 August 2017

J Edenfield

5

1 reference

Europe PubMed Central

2 August 2017

J Fiorica

6

1 reference

Europe PubMed Central

2 August 2017

J Stephenson

7

1 reference

Europe PubMed Central

2 August 2017

L P Martin

8

1 reference

Europe PubMed Central

2 August 2017

S Westin

9

1 reference

Europe PubMed Central

2 August 2017

P Hanjani

10

1 reference

Europe PubMed Central

2 August 2017

M B Jones

11

1 reference

Europe PubMed Central

2 August 2017

K Almhanna

12

1 reference

Europe PubMed Central

2 August 2017

R M Wenham

13

1 reference

Europe PubMed Central

2 August 2017

D M Sullivan

14

1 reference

Europe PubMed Central

2 August 2017

W S Dalton

15

1 reference

Europe PubMed Central

2 August 2017

A Gunchenko

16

1 reference

Europe PubMed Central

2 August 2017

J D Cheng

17

1 reference

Europe PubMed Central

2 August 2017

L L Siu

18

1 reference

Europe PubMed Central

2 August 2017

J E Gray

19

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

7 October 2014

1 reference

Europe PubMed Central

2 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

2 August 2017

111

1 reference

Europe PubMed Central

2 August 2017

1932-1944

1 reference

Europe PubMed Central

2 August 2017

10

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.2014.497

0 references

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Insulin-like growth factor receptor inhibitors: baby or the bathwater?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Targeting the Notch pathway: twists and turns on the road to rational therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Notch signalling in solid tumours: a little bit of everything but not all the time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

A modified toxicity probability interval method for dose-finding trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

The IGF‐1 receptor in cancer biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229637

7 July 2018

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

21 January 2018

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25290091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticancer IGF1R classes take more knocks

1 reference

https://pubmed.ncbi.nlm.nih.gov/25290091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25290091

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.497

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BJC.2014.497

1 reference

https://api.fatcat.wiki/v0/release/c4iik4j4arbcva7lpz4q64tk74

30 July 2022

based on heuristic

mapped directly with Wikidata item

Dimensions Publication ID

0 references

release_c4iik4j4arbcva7lpz4q64tk74

1 reference

https://api.fatcat.wiki/v0/release/c4iik4j4arbcva7lpz4q64tk74

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/c4iik4j4arbcva7lpz4q64tk74

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/c4iik4j4arbcva7lpz4q64tk74

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34499662&oldid=1801831604"